Maximizing the Delivery of Intraperitoneal Therapy While Minimizing Drug Toxicity and Maintaining Quality of Life

David S Alberts, Ardie Delforge

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

This decade has witnessed three large randomized trials (SWOG 8501/GOG 104, GOG 114, and GOG 172) clearly showing the advantages of intraperitoneal (IP) chemotherapy over systemic/intravenous therapy in treating selected patients with advanced stage ovarian cancer. Despite showing an impressive increase in median progression-free survival and median overall survival, complications in IP chemotherapy delivery and drug-related toxicities reported in these studies have hindered widespread acceptance and implementation of first-line IP therapy. Some of these complications and drug-related toxicities are treatment-limiting and need special attention. Success of IP therapy as a first-line choice of treatment is dependent upon ideal patient selection, effective delivery of appropriate doses of chemotherapy agents to the tumor site, and efficient management of complications. With proper orientation and instruction in IP catheter placement and patient management, these obstacles can be overcome, allowing for successful administration of IP therapies. This review article discusses clinical approaches to maximize the delivery of IP therapy while minimizing catheter complications. Mitigating drug toxicities with the use of cytoprotectants such as amifostine and preventing infection with the use of agents, such as amifostine and pegfilgrastim, are discussed in detail.

Original languageEnglish (US)
Pages (from-to)8-17
Number of pages10
JournalSeminars in Oncology
Volume33
Issue numberSUPPL. 12
DOIs
StatePublished - Dec 2006

Fingerprint

Drug-Related Side Effects and Adverse Reactions
Quality of Life
Amifostine
Drug Therapy
Therapeutics
Catheters
Ovarian Neoplasms
Patient Selection
Disease-Free Survival
Survival
Infection
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Maximizing the Delivery of Intraperitoneal Therapy While Minimizing Drug Toxicity and Maintaining Quality of Life. / Alberts, David S; Delforge, Ardie.

In: Seminars in Oncology, Vol. 33, No. SUPPL. 12, 12.2006, p. 8-17.

Research output: Contribution to journalArticle

@article{2c97387b32254141bdfc3c1ef6bfbdfc,
title = "Maximizing the Delivery of Intraperitoneal Therapy While Minimizing Drug Toxicity and Maintaining Quality of Life",
abstract = "This decade has witnessed three large randomized trials (SWOG 8501/GOG 104, GOG 114, and GOG 172) clearly showing the advantages of intraperitoneal (IP) chemotherapy over systemic/intravenous therapy in treating selected patients with advanced stage ovarian cancer. Despite showing an impressive increase in median progression-free survival and median overall survival, complications in IP chemotherapy delivery and drug-related toxicities reported in these studies have hindered widespread acceptance and implementation of first-line IP therapy. Some of these complications and drug-related toxicities are treatment-limiting and need special attention. Success of IP therapy as a first-line choice of treatment is dependent upon ideal patient selection, effective delivery of appropriate doses of chemotherapy agents to the tumor site, and efficient management of complications. With proper orientation and instruction in IP catheter placement and patient management, these obstacles can be overcome, allowing for successful administration of IP therapies. This review article discusses clinical approaches to maximize the delivery of IP therapy while minimizing catheter complications. Mitigating drug toxicities with the use of cytoprotectants such as amifostine and preventing infection with the use of agents, such as amifostine and pegfilgrastim, are discussed in detail.",
author = "Alberts, {David S} and Ardie Delforge",
year = "2006",
month = "12",
doi = "10.1053/j.seminoncol.2006.11.003",
language = "English (US)",
volume = "33",
pages = "8--17",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 12",

}

TY - JOUR

T1 - Maximizing the Delivery of Intraperitoneal Therapy While Minimizing Drug Toxicity and Maintaining Quality of Life

AU - Alberts, David S

AU - Delforge, Ardie

PY - 2006/12

Y1 - 2006/12

N2 - This decade has witnessed three large randomized trials (SWOG 8501/GOG 104, GOG 114, and GOG 172) clearly showing the advantages of intraperitoneal (IP) chemotherapy over systemic/intravenous therapy in treating selected patients with advanced stage ovarian cancer. Despite showing an impressive increase in median progression-free survival and median overall survival, complications in IP chemotherapy delivery and drug-related toxicities reported in these studies have hindered widespread acceptance and implementation of first-line IP therapy. Some of these complications and drug-related toxicities are treatment-limiting and need special attention. Success of IP therapy as a first-line choice of treatment is dependent upon ideal patient selection, effective delivery of appropriate doses of chemotherapy agents to the tumor site, and efficient management of complications. With proper orientation and instruction in IP catheter placement and patient management, these obstacles can be overcome, allowing for successful administration of IP therapies. This review article discusses clinical approaches to maximize the delivery of IP therapy while minimizing catheter complications. Mitigating drug toxicities with the use of cytoprotectants such as amifostine and preventing infection with the use of agents, such as amifostine and pegfilgrastim, are discussed in detail.

AB - This decade has witnessed three large randomized trials (SWOG 8501/GOG 104, GOG 114, and GOG 172) clearly showing the advantages of intraperitoneal (IP) chemotherapy over systemic/intravenous therapy in treating selected patients with advanced stage ovarian cancer. Despite showing an impressive increase in median progression-free survival and median overall survival, complications in IP chemotherapy delivery and drug-related toxicities reported in these studies have hindered widespread acceptance and implementation of first-line IP therapy. Some of these complications and drug-related toxicities are treatment-limiting and need special attention. Success of IP therapy as a first-line choice of treatment is dependent upon ideal patient selection, effective delivery of appropriate doses of chemotherapy agents to the tumor site, and efficient management of complications. With proper orientation and instruction in IP catheter placement and patient management, these obstacles can be overcome, allowing for successful administration of IP therapies. This review article discusses clinical approaches to maximize the delivery of IP therapy while minimizing catheter complications. Mitigating drug toxicities with the use of cytoprotectants such as amifostine and preventing infection with the use of agents, such as amifostine and pegfilgrastim, are discussed in detail.

UR - http://www.scopus.com/inward/record.url?scp=33846107539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846107539&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2006.11.003

DO - 10.1053/j.seminoncol.2006.11.003

M3 - Article

C2 - 17223445

AN - SCOPUS:33846107539

VL - 33

SP - 8

EP - 17

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - SUPPL. 12

ER -